Form 8-K Aerovate Therapeutics, For: Jun 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Form 8-K Aerovate Therapeutics, For: Jun 17
June 17, 2024 4:06 PM EDT
TD Cowen analyst Joseph Thome downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Hold.
The analyst comments "Aerovate announced AV-101 did not achieve either the primary PVR endpoint or key secondary 6MWD endpoint for the Ph. IIb portion of the... More
June 17, 2024 4:01 PM EDT
Evercore ISI analyst Liisa Bayko downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Outperform to In Line with a price target of $2.00 (from $27.00).
The analyst ocmments "AV-101, inhaled form of imatinib, was an abject failure in PAH, showing no clinically relevant benefit on PVR... More
June 17, 2024 12:15 PM EDT
Jefferies analyst Eun Yang downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Hold with a price target of $2.00 (from $65.00).
The analyst comments "AVTE announced that the Phase IIB failed in PAH and that none of the 3 doses demonstrated a clinically meaningful improvement in PVR.... More
June 17, 2024 10:39 AM EDT
BTIG analyst Julian Harrison downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Neutral.
The analyst comments "AV-101 did not separate from placebo on its primary endpoint in the Phase 2b portion of IMPAHCT. All doses of AV-101 failed to meet stat sig on PVR at... More
